(Q27001269)

neoplastic gene expression regulation

inferred from abstract

1 reference

4 November 2020

1 reference

18 December 2019

1 reference

14 September 2020

1 reference

4 November 2020

1 reference

Dong Yang

1

1 reference

Min-Bin Chen

2

1 reference

Li-Qiang Wang

3

1 reference

Lan Yang

4

1 reference

Chao-Ying Liu

5

1 reference

Pei-Hua Lu

6

1 reference

Journal of Experimental & Clinical Cancer Research

language of work or name

1 reference

27 December 2013

10 references

13 March 2019

3 April 2019

17 June 2019

2 August 2019

8 September 2019

20 November 2019

18 December 2019

14 September 2020

4 November 2020

8 references

17 June 2019

2 August 2019

8 September 2019

20 November 2019

18 December 2019

14 September 2020

4 November 2020

32

1 reference

page(s)

105

1 reference

Creative Commons Attribution 2.0 Generic

copyright license

9 references

13 March 2019

3 April 2019

17 June 2019

2 August 2019

8 September 2019

20 November 2019

18 December 2019

14 September 2020

on focus list of Wikimedia project

4 November 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1756-9966-32-105

0 references

cites work

Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Measuring inconsistency in meta-analyses

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Reporting results of cancer treatment

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Control of mitochondrial apoptosis by the Bcl-2 family

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Predictive factors for response to docetaxel in human breast cancers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer.

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-32-105

Apoptosis induced by neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-32-105

High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-32-105

The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-32-105

Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-32-105

Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-32-105

Assessment of predictive markers of response to neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-32-105

Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3922829

Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression

28 November 2018

1 reference

12 December 2020

Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer

1 reference

12 December 2020

Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer

1 reference

12 December 2020

Low expression of NQO1 predicts pathological complete response to neoadjuvant chemotherapy in breast cancer patients treated with TAC regimen

1 reference

12 December 2020

Prediction of response to primary chemotherapy for operable breast cancer

1 reference

12 December 2020

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients

1 reference

12 December 2020

The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile

1 reference

12 December 2020

A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer

1 reference

12 December 2020

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas

1 reference

12 December 2020

Clinicopathologic Analysis of Fas, Fas Ligand, and Other Biomarkers in Locally Advanced Breast Carcinoma

1 reference

12 December 2020

Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN)

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-9966-32-105

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

5040063

Dimensions Publication ID

1035017650

0 references

Fatcat ID

release_lqcnjjvghjazdg4p3fpjnu4u3q

0 references

OpenCitations bibliographic resource ID

5040063

1 reference